Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2011

View Archived Issues

SPINK1 identified as potential therapeutic target in prostate cancer

GSK-3 inhibitor SC-001 may have potential for the treatment of Parkinson's disease

Neuroprotective efficacy hypothesized for Klotho enhancers

New dual DPP IV/AP-N inhibitors prepared by IMTM

Research Development Foundation patents novel urocortin-2 analogues

New B-raf inhibitors reported by Array BioPharma and Genentech

Lilly and Avid receive FDA complete response letter for Amyvid

Vardenafil plus tamsulosin improves LUTS in subjects with BPH in long-term study

CHMP recommends approval of Lucentis in new indication

Nerviano enters into oncology license agreement with Novartis

CHMP adopts negative opinion for Vectibix in combination with chemotherapy

Insys Therapeutics reports phase III data for fentanyl sublingual spray

Lonza and Athera sign development and manufacturing agreement for PC-mAb

Scientists at Anacor Pharmaceuticals prepare new antiprotozoal agents

Regeneron and sanofi-aventis begin phase II trial of MAb SAR-231893 in eosinophilic asthma

University of Pennsylvania designs novel adamantane analogues for influenza and related disorders

Euthymics Bioscience begins EB-1010 trial for major depression

KAI Pharmaceuticals begins enrollment of phase II study of KAI-4169 in secondary hyperparathyroidism

Polaris begins enrollment in phase II trial of ADI-PEG 20 in malignant mesothelioma

KineMed extends collaboration with Bristol-Myers Squibb for Alzheimer's disease

Genentech's pivotal trial of vismodegib in advanced basal cell carcinoma meets primary endpoint

CHMP adopts positive opinion regarding new birth control pill NOMAC/E2

Septodont acquires local anesthesia reversal agent OraVerse from Novalar

Quark terminates phase II study of PF-04523655 early, plans phase IIb study

Cell Therapeutics opens enrollment in pivotal PIX-R trial of pixantrone

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...